Financial Perspectives Inc Has $85,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Financial Perspectives Inc decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 53.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 607 shares of the life sciences company’s stock after selling 691 shares during the quarter. Financial Perspectives Inc’s holdings in Illumina were worth $85,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Global Retirement Partners LLC increased its position in shares of Illumina by 36.5% in the third quarter. Global Retirement Partners LLC now owns 714 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 191 shares during the last quarter. Avior Wealth Management LLC increased its position in shares of Illumina by 9.9% in the third quarter. Avior Wealth Management LLC now owns 3,327 shares of the life sciences company’s stock valued at $457,000 after acquiring an additional 300 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management increased its position in shares of Illumina by 72.5% in the third quarter. B & T Capital Management DBA Alpha Capital Management now owns 16,647 shares of the life sciences company’s stock valued at $2,285,000 after acquiring an additional 6,999 shares during the last quarter. Romano Brothers AND Company acquired a new stake in shares of Illumina in the third quarter valued at about $1,691,000. Finally, Royal Fund Management LLC increased its position in shares of Illumina by 5.9% in the third quarter. Royal Fund Management LLC now owns 5,702 shares of the life sciences company’s stock valued at $783,000 after acquiring an additional 320 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 3.5 %

Shares of NASDAQ:ILMN traded up $4.21 during trading on Tuesday, hitting $124.46. 1,302,988 shares of the company were exchanged, compared to its average volume of 1,745,510. The business’s 50 day moving average is $132.98 and its 200-day moving average is $127.68. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $229.58.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.14 earnings per share. Sell-side analysts predict that Illumina, Inc. will post 0.91 EPS for the current year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of a number of recent research reports. Barclays lifted their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a report on Thursday, January 4th. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Finally, StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.